Catalyst Wire Dossier Catalyst Wire Dossier

Optive MEGA-3 (OM3)

Omega-3 fatty acid-containing ocular product · AbbVie
Drug timelines are a Plus or Pro feature.

1 regulatory and trial event tracked for Optive MEGA-3 (OM3), covering 2025-08-19 to 2025-08-19. Get the full timeline:

Most recent: Clinical Trial Update: An Observational Study to Assess Optive MEGA-3 (OM3) on Dry Eye Symptoms and Quality of Life of Adult Participants With Mild to Moderate Dry Eye Disease (DED)

See pricing